Home > Insider Trading > Filing (0000899243-20-028807)

Filing Details

Accession Number:: 0000899243-20-028807
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-20 20:05:15
Reporting Period:: 2020-10-16

Accepted Time:: 2020-10-20 20:05:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659352	Codiak Biosciences Inc.	CDAK	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1627639	Flagship Ventures Fund V, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1724575	Flagship Ventures Fund V General Partner Llc	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1724939	Flagship V Venturelabs Rx Fund, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-16	543,686	$0.00	543,686	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	543,686	$0.00	543,686	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	338,630	$0.00	882,316	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	338,630	$0.00	882,316	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	95,861	$0.00	978,177	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	95,861	$0.00	978,177	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	165,000	$15.00	1,143,177	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-16	4,250,000	$0.00	543,686	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-10-16	4,250,000	$0.00	543,686	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-16	2,416,666	$0.00	338,630	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-16	2,416,666	$0.00	338,630	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-10-16	660,048	$0.00	95,861	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-10-16	660,048	$0.00	95,861	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	485,949	Indirect	See Footnote

Footnotes

Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.8170 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date.
Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. serves as the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Each share of Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.1366 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Fund V is a member of VentureLabs V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The general partner of Flagship Fund V is Flagship V GP. Noubar B. Afeyan, Ph.D. serves as the sole director of Flagship Pioneering and as the sole manager of Flagship V GP. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.